Just How Positive is Stifel on Hologic (NASDAQ:HOLX) Following Its Upgrade? The Target PPS is $45.0


Hologic (NASDAQ:HOLX) Stock Upgrade

Stifel lifted shares of Hologic (NASDAQ:HOLX) from a “Hold” rating to a solid “Buy” rating in an analyst note issued to investors and clients on 11 December. The firm after the upgrade has a $45.0 Estimated Target Price on shares.

From a total of 15 analysts covering Hologic (NASDAQ:HOLX) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 10 a ”Hold”. This means that 52% of the ratings are positive. The highest target price is $50 while the lowest target price is $33. The mean of all analyst targets is $42.07 with a 19.67% above today’s ($37.77) stock price. Hologic was the topic of 8 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. BTIG Research upgraded shares on October 26 to “Buy” rating. Argus Research maintained shares with “Buy” rating and $52 target share price in a report from an August 3. Craig Hallum downgraded HOLX stock in a recent report from October 21 to “Hold” rating. Barclays Capital maintained the rating on July 30. Barclays Capital has a “Underweight” rating and a $40 price target on shares. Finally, Barclays Capital upgraded the stock to “Equal Weight” rating in a report issued on a September 2.

The stock increased 0.75% or $0.28 during the last trading session, striking $37.77. Approximately 100 shares of stock traded hands. Hologic, Inc. (NASDAQ:HOLX) has risen 11.12% since May 8, 2015 and is uptrending. It has outperformed by 14.14% the S&P500.

The overall sentiment of institutions has increased to 1.28 in Q2 2015. Its up 0.34, from 0.94 in 2015Q2. The ratio improved, as 31 institutions have sold all the shares of Hologic, Inc. that they owned while 138 funds have taken shares off the table. 66 funds have purchased shares for the first time while 151 added to their positions. These institutions now hold 281.67 million shares or 2.60% more than the 274.53 million shares they owned in 2015Q2.

The Fund Relational Investors Llc currently is holding shares equating to 34.54% of its total portfolio in Hologic, Inc. representing a total of 7.42 million shares. Another fund,Tiger Eye Capital Llc, is holding a total of 1.07 million shares equating to 5.71% of their holdings. Additionally, Lateef Investment Management L.P. has a 5.29 million share stake in Hologic, Inc. which represents 5.05% of their total portfolio. The Fund, Domini Social Investments Llc, based out of New York, has also built up a stake in the stock, which represents a total of 4.44% of their total portfolio. Finally American Capital Management Inc, a fund which is based in the state of New York reported a total holdings of 1.01 million shares.

Insider activity is a very important aspect to track on any stock. Going back to March 9, 2015, shareholders of Hologic, Inc. have witnessed 0 buys, and a total of 9 selling transactions equating to a net activity of approximately $254.29 million . Levy Lawrence M sold 5,000 shares worth approximately $210,113. Wilson Wayne sold 100,000 shares worth approximately $3.90M. Lavance David R Jr sold 97,410 shares worth approximately $4.09 million. Icahn Carl C sold 6.00M shares worth approximately $242.82M. The company insider Oberton Karleen Marie sold 15,000 shares worth $620,400.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The company has a market cap of $10.61 billion. The Company’s business units are focused on diagnostics, breast health, GYN surgical and skeletal health. It has 83.69 P/E ratio. The Company’s diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays.

According to Zacks Investment Research, “Hologic Inc. is a leading supplier of high quality, innovative and clinically valuable diagnostic systems and tests. The company develops, manufactures and markets X-ray bone densitometers and ultrasound bone analyzers that address a growing market for osteoporosis prevention and treatment — a key element of women’s health care. The systems are used by more leading medical schools, universities and osteoporosis opinion leaders than any other bone densitometer.” Get a free copy of the Zacks research report on Hologic, Inc. (HOLX).